Hepatocellular carcinoma (HCC) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-WILSONS-DISEASE-HCC-PREVENTION-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-AASLD-HCC-2023` `SRC-NCCN-BCELL-2025` `SRC-NCCN-HCC-2025`

Notes

STUB — v0.3 chronic-condition prevention pilot (Wilson's / HCC). Two-Co-Lead signoff queued. AASLD 1.5%/year surveillance threshold in Wilson's cirrhosis is well-supported in contemporary cohorts; older literature suggesting near-zero HCC risk in Wilson's reflects pre-transplant-era short-follow-up bias.

Used By

Indication

IND-WILSONS-DISEASE-HCC-PREVENTION-OBSERVATION - IND-WILSONS-DISEASE-HCC-PREVENTION-OBSERVATION

Red flag

RF-WILSONS-DISEASE-HCC-PREVENTION - Wilson's disease (autosomal recessive ATP7B-mutated copper-transport disorder with hepati...